Helping The others Realize The Advantages Of HOIPIN-1
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To judge several intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Principal demo aims were being To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clie